Navigation Links
Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
Date:10/6/2008

SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) will host a conference call today, Monday, October 6, 2008 at 9:00 AM ET (6:00 AM PT) to review the outcome of the interim analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Those interested may access the call with the following information:

Time: 9:00 AM ET/6:00 AM PT

Date: October 6, 2008

Dial-in: 1-877-419-6598 (domestic) or +1-719-325-4935 (international)

Webcast: http://www.dendreon.com (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457- 0820 for international callers; the conference ID number is 5304314. The replay will be available from 2:00 pm ET on Monday, October 6, 2008 until midnight ET on Wednesday, October 8, 2008. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it has concluded agreements with the U.S. Department of ... (SEC) to resolve the previously disclosed U.S. Foreign Corrupt ... as in relation to the former deferred prosecution agreement ... with DOJ and SEC, respectively, on March 26, 2012.  ...
(Date:1/12/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... findings at this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) ... acnes -induced inflammation. The data will be shared ... Acne Pathogenesis," at ODAC, which is being held Jan. 13-16 ... ...
(Date:1/12/2017)... -- This new report from VPGMarketResearch contains 897 pages, ... German hospital microbiology testing market, including:  ... practice, as well as key economic, regulatory, demographic, social ... next ten years.  ... of major infectious diseases and microorganisms.  ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... ... 2017 , ... Healthy living brand Moody Zook recently came ... With more and more people opting to go organic in their lifestyle, the ... to specific needs. , Moody Zook focused particularly on their newly launched activated ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... that raise blood sugar levels. Counting carbohydrates is as easy as checking the ... only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can influence ...
(Date:1/13/2017)... ... January 13, 2017 , ... With ... on the challenge of providing additional organic alternatives for customers who have grown ... the brand’s new line of all-natural activated charcoal products, Moody Zook Chief Executive ...
Breaking Medicine News(10 mins):